Document is current
Any future updates will be listed below
-
Authors
Komatsu, Mitsuhisa
Kobayashi, Hiroshi
Tsuboi, Satoshi
Watada, Hirotaka
-
Funding
Funding for this research was provided by:
Novo Nordisk Pharma Ltd (Novo Nordisk Pharma Ltd)
- License Information
-
More Information
Article History
Received: 28 August 2025
Accepted: 7 January 2026
First Online: 17 March 2026
Declarations
:
: Mitsuhisa Komatsu has received honoraria for lectures from Nippon Boehringer Ingelheim Co. Ltd., Ono Pharmaceutical Co., Ltd., MSD, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Sumitomo Pharma Co. Ltd., Teijin Pharma Ltd., Novo Nordisk Pharma Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Daiichi Sankyo Company Ltd., Eli Lilly Japan K., and Kowa Pharmaceutical Co., and for research activities for Novo Nordisk Pharma Ltd. Hirotaka Watada has received honoraria for lectures for Sumitomo Pharma, Taisho, Embecta, GSK, Sanofi, Kowa, Bayer, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Mitsubishi Tanabe, Abott Japan, Teijin, Roche DC Japan, MSD, Sanwa Kagaku Kenkyusyo, Daiichi Sankyo, Kyowa Kirin, and for research activities for Sumitomo Pharma, Taisho, SBI Pharma, Kowa, Sanwa Kagaku Kenkyusyo, Boehringer Ingelheim, Teijin, Abott Japan, Lifescan Japan, Takeda, Sougoui kagakuken kyusho. Satoshi Tsuboi and Hiroshi Kobayashi are employed by Novo Nordisk Pharma Ltd. Hiroshi Kobayashi hold RSU for Novo Nordisk Pharma Ltd.
: This study used secondary data, provided by Medical Data Vision (MDV) Co., Ltd. (Tokyo, Japan) and collected from approximately 450 hospitals that had provided consent for secondary use of data.
